Digestive Diseases and Sciences

, Volume 47, Issue 8, pp 1705–1715 | Cite as

Resource Utilization Associated with Irritable Bowel Syndrome in the United States: 1987–1997

  • Ya-Chen Tina Shih
  • Victoria E. Barghout
  • Robert S. Sandler
  • Priti Jhingran
  • Medha Sasane
  • Suzanne Cook
  • David C. Gibbons
  • Michael Halpern


This study uses national databases to examine the impact of irritable bowel syndrome (IBS) on resource utilization in the United States. Approximately 1.5–2.7 million physician visits (599–1043 per 100,000) yearly were related to IBS, with 45.3% seen by gastroenterologists, and 89% prescribed medications. Rates of physician visits by women were approximately 2.4–3.3 times higher than that for men. The average number of medication prescribed per visit was 1.83. Approximately 89% of the visits were prescribed with medications. The rate of hospitalization (5.1 per 100,000 in 1997) decreased by 60% and length of stay decreased from 5.5 to 3.1 days in the past decade. The average charges of IBS-related hospitalization were US$7,882. Our study found an apparent decreasing trend of IBS-related hospitalizations and no marked increase in office consultations in the past decade. However, a better case identification criterion is necessary to estimate the true disease burden.

irritable bowel syndrome resource utilization National Ambulatory Medical Care Survey National Disease and Therapeutic Index National Hospital Discharge Survey National Inpatient Sample Healthcare Cost and Utilization Project 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Thompson, Longstreth GF, Drossman DA, et al: Functional bowel disorders and functional abdominal pain. Gut 45(suppl 2):II43–II47, 1999PubMedGoogle Scholar
  2. 2.
    Russo MW, Gaynes BN, Drossman DA: A national survey of practice patterns of gastroenterologists with comparison to the past two decades. J Clin Gastroenterology 29(4):339–343, 1999Google Scholar
  3. 3.
    Gershon MD. 5-HT (serotonin) physiology and related drugs. Curr Opin Gastroenterol 16:113–120, 2000Google Scholar
  4. 4.
    Baxendale A, Bountra C, Clayton N, et al: Irritable bowel syndrome as visceral hyperalgesia: implications for therapy? Curr Opin CPNS Invest Drugs 1:86–97, 1999Google Scholar
  5. 5.
    Harris MS: Irritable bowel syndrome: A cost-effective approach for primary care physicians. Postgrad Med 101(3):215–226, 1997PubMedGoogle Scholar
  6. 6.
    Paterson WG, Thompson WG, Vanner SI, et al: Recommendations for the management of irritable bowel syndrome in family practice. Can Med Asso J 161(2):154–160, 1999Google Scholar
  7. 7.
    Sandler RS: Epidemiology of irritable bowel syndrome in the United States. Gastroenterology 99:409–415, 1990PubMedGoogle Scholar
  8. 8.
    Talley N, Zinsmeister A, Van Dyke C, Melton J: Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 101:927–934, 1991PubMedGoogle Scholar
  9. 9.
    Drossman D, Zhiming Li, Andruzzi E, et al: US householder survey of functional gastrointestinal disorders; Prevalence, sociodemography, and health impact. Dig Dis Sci 38(9):1569–1580, 1993PubMedGoogle Scholar
  10. 10.
    Camilleri M, Choi M: Irritable bowel syndrome. Ailment Pharmacol Ther 11:3–15, 1997Google Scholar
  11. 11.
    Agreus L: The epidemiology of functional gastrointestinal disorders. Eur J Surg Suppl 583:60–66, 1998Google Scholar
  12. 12.
    Everhart JE, Renault PF: Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 100:998–1005, 1991PubMedGoogle Scholar
  13. 13.
    Farthing M: Irritable bowel syndrome: New pharmaceutical approaches to treatment, Ballieres Clin Gastroenterol 13:61–71, 1999Google Scholar
  14. 14.
    National Center of Health Statistics: National Ambulatory Medical Care Survey 1997. Public-use data file and documentation. Statistics/NCHS/ 1999Google Scholar
  15. 15.
    1997 National Disease and Therapeutic Index: IMS Health. Plymouth Meeting PennsylvaniaGoogle Scholar
  16. 16.
    National Center of Health Statistics: National Hospital Discharge Survey, 1997. Public-use data file and documentation. Statistics/NCHS/ 1999Google Scholar
  17. 17.
    Department of Health and Human Services: International classification of diseases, Clinical modification, 9th rev., 5th ed. US Public Health Service, Health Care Financing Administration. 1994Google Scholar
  18. 18.
    International Classification of Diseases, Clinical Modification, 9th rev., 5th ed. Salt Lake City, Utah, Medicode Publications, 1996Google Scholar
  19. 19.
    SAS Institute: SAS Version 6.12, SAS Institute, Cary, North CarolinaGoogle Scholar
  20. 20.
    Lynn R, Friedman L: Current concepts: Irritable bowel syndrome. N Engl J Med 329:1940–1944, 1993PubMedGoogle Scholar
  21. 21.
    Drossman D: Irritable bowel syndrome and sexual/physical abuse history. Eur J Gastroenterol Hepatol 9:327–330, 1997PubMedGoogle Scholar
  22. 22.
    Bonis P, Norton R: The challenge of irritable bowel syndrome. Am Fam Physician 53:1229–1235, 1996PubMedGoogle Scholar
  23. 23.
    Camilleri M, Choi MG: Clinical evidence to support current therapies of irritable bowel syndrome. Aliment Pharmacol Ther 13(suppl 2):48–53, 1999PubMedGoogle Scholar
  24. 24.
    Dixon-Woods M, Critchley S: Medical and lay views of irritable bowel syndrome. Fam Pract 17:108–113, 2000PubMedGoogle Scholar
  25. 25.
    Iezzoni L (ed): Risk adjustment for measuring healthcare outcomes. Chicago, Health Administration Press, 1997Google Scholar
  26. 26.
    Kozak LJ, Lawrence L: National hospital discharge survey: Annual summary, 1997. National Center for Health Statistics. Vital Health Stat 139:144, 1999Google Scholar
  27. 27.
    Inglehart JK: The American health care system—expenditures. N Engl J Med 340:70–76, 1999PubMedGoogle Scholar
  28. 28.
    Talley NJ, Zinsmeister AR, Melton LJ: Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol. 142(1):76–83, 1995PubMedGoogle Scholar
  29. 29.
    McFarland B: Comparing period prevalences with application to drug utilization. J Clin Epidemiol 49:473–482, 1996PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 2002

Authors and Affiliations

  • Ya-Chen Tina Shih
    • 1
  • Victoria E. Barghout
    • 2
  • Robert S. Sandler
    • 3
  • Priti Jhingran
    • 4
  • Medha Sasane
    • 5
  • Suzanne Cook
    • 4
  • David C. Gibbons
    • 4
  • Michael Halpern
    • 6
  1. 1.MEDTAP International Inc.BethesdaUSA
  2. 2.Novartis Pharmaceutical CorporationEast HanoverUSA
  3. 3.University of North CarolinaChapel HillUSA
  4. 4.Research Triangle ParkGlaxoSmithKline Inc., U.S. Medical Affairs Health OutcomesNorth CarolinaUSA
  5. 5.Research Triangle ParkStrategic Outcomes Services of Care Science Inc.North CarolinaUSA
  6. 6.Exponent Inc.AlexandriaUSA

Personalised recommendations